TP53-altered AML cell lines were found to have higher aneuploidy scores indicating chromosomal instability, and notably more resistant to etoposide, a chemotherapeutic drug commonly used in pediatric AML treatment (Fig. 6b). This evidence concerns the gene TP53 and acute myeloid leukemia.